Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Patients with the genetic foundation to marshal an efficient, rapid response to the H5N1 influenza virus are more likely than others to survive the bird flu, according to a team led by St. Jude investigators.
As home to the only World Health Organization collaborating center focusing on the transmission of animal influenza viruses to humans, St. Jude is closely monitoring the H1N1 pandemic.
As the world watches the developing story of the influenza A (H1N1) outbreak, St. Jude Children’s Research Hospital is working collaboratively with other research centers to help develop an effective vaccine.
Richard Webby, PhD, an associate member in Infectious Diseases, has been named director of the World Health Organization (WHO) Collaborating Center for Studies on the Ecology of Influenza Viruses in Lower Animals and Birds.
The yearly influenza vaccine that health officials urge people to get each fall might also offer certain individuals some cross protection against the H5N1 virus commonly known as bird flu, according to St. Jude investigators.
The emergence of the bird flu virus H5N1 that is currently devastating chicken flocks in many countries and threatening to unleash a worldwide epidemic among humans has triggered a renewed interest among scientists in studying influenza A viruses.
St. Jude has been named by Scientific American magazine as a research leader within the 2004 Scientific American 50, the magazine's prestigious annual list recognizing outstanding acts of leadership in science and technology.
An avian influenza virus that has caused three major outbreaks among poultry and killed several people in East Asia over the past seven years arose through a series of genetic reassortment events with other viruses.
Scientists at St. Jude Children's Research Hospital announced today the development of a vaccine against H5N1, a new lethal influenza virus that triggered the World Health Organization (WHO) to declare a pandemic alert in February 2003.